Last 2 Days: Watch the Replay of Great Indian Wealth Project Special Event
Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -1.2 |
No. of shares | m | 282.17 |
% ch week | % | -5.4 |
% ch 1-mth | % | -4.9 |
% ch 12-mth | % | 59.9 |
52 week H/L | Rs | 572.7/168.0 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
GLENMARK PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 879 | 1,262 | 993 | 930 | 712 | |
Low | Rs | 752 | 672 | 729 | 517 | 484 | |
Sales per share (Unadj.) | Rs | 244.4 | 271.1 | 325.5 | 322.6 | 349.6 | |
Earnings per share (Unadj.) | Rs | 17.5 | 26.3 | 39.3 | 28.5 | 32.8 | |
Diluted earnings per share | Rs | 16.8 | 26.3 | 39.3 | 28.5 | 32.8 | |
Cash flow per share (Unadj.) | Rs | 27.1 | 34.6 | 48.7 | 39.2 | 44.3 | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
Adj. dividends per share | Rs | 1.92 | 2.00 | 2.00 | 2.00 | 2.00 | |
Dividend yield (eoy) | % | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | |
Book value per share (Unadj.) | Rs | 86.1 | 128.6 | 159.2 | 183.0 | 198.6 | |
Adj. book value per share | Rs | 82.8 | 128.6 | 159.2 | 183.0 | 198.6 | |
Shares outstanding (eoy) | m | 271.29 | 282.16 | 282.17 | 282.17 | 282.17 | |
Bonus/Rights/Conversions | - | - | ESOP | - | - | ||
Price / Sales ratio | x | 3.3 | 3.6 | 2.6 | 2.2 | 1.7 | |
Avg P/E ratio | x | 46.6 | 36.7 | 21.9 | 25.4 | 18.2 | |
P/CF ratio (eoy) | x | 30.1 | 27.9 | 17.7 | 18.5 | 13.5 | |
Price / Book Value ratio | x | 9.5 | 7.5 | 5.4 | 4.0 | 3.0 | |
Dividend payout | % | 11.4 | 7.6 | 5.1 | 7.0 | 6.1 | |
Avg Mkt Cap | Rs m | 221,284 | 272,778 | 242,991 | 204,206 | 168,625 | |
No. of employees | `000 | 9.5 | 10.0 | 13.0 | 13.7 | 12.0 | |
Total wages/salary | Rs m | 12,024 | 13,782 | 16,408 | 18,718 | 20,561 | |
Avg. sales/employee | Rs Th | 6,961.1 | 7,630.5 | 7,083.9 | 6,636.8 | 8,196.0 | |
Avg. wages/employee | Rs Th | 1,262.5 | 1,374.8 | 1,265.4 | 1,364.7 | 1,708.1 | |
Avg. net profit/employee | Rs Th | 499.0 | 741.2 | 855.1 | 586.1 | 768.5 |
GLENMARK PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 66,298 | 76,496 | 91,857 | 91,031 | 98,655 | |
Other income | Rs m | 219 | 200 | 374 | 914 | 2,081 | |
Total revenues | Rs m | 66,516 | 76,696 | 92,230 | 91,945 | 100,736 | |
Gross profit | Rs m | 10,225 | 14,372 | 20,367 | 16,154 | 15,858 | |
Depreciation | Rs m | 2,600 | 2,343 | 2,644 | 3,019 | 3,259 | |
Interest | Rs m | 1,902 | 1,789 | 2,373 | 2,856 | 3,346 | |
Profit before tax | Rs m | 5,943 | 10,440 | 15,724 | 11,193 | 11,335 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | -810 | 0 | 1,672 | |
Tax | Rs m | 1,190 | 3,009 | 3,827 | 3,155 | 3,756 | |
Profit after tax | Rs m | 4,752 | 7,430 | 11,088 | 8,039 | 9,250 | |
Gross profit margin | % | 15.4 | 18.8 | 22.2 | 17.7 | 16.1 | |
Effective tax rate | % | 20.0 | 28.8 | 24.3 | 28.2 | 33.1 | |
Net profit margin | % | 7.2 | 9.7 | 12.1 | 8.8 | 9.4 |
GLENMARK PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 53,199 | 59,043 | 68,746 | 69,887 | 66,968 | |
Current liabilities | Rs m | 37,111 | 39,993 | 27,027 | 32,879 | 40,211 | |
Net working cap to sales | % | 24.3 | 24.9 | 45.4 | 40.7 | 27.1 | |
Current ratio | x | 1.4 | 1.5 | 2.5 | 2.1 | 1.7 | |
Inventory Days | Days | 70 | 75 | 85 | 81 | 83 | |
Debtors Days | Days | 138 | 119 | 96 | 93 | 81 | |
Net fixed assets | Rs m | 17,445 | 21,416 | 24,132 | 28,892 | 33,322 | |
Share capital | Rs m | 271 | 282 | 282 | 282 | 282 | |
"Free" reserves | Rs m | 23,086 | 36,014 | 44,643 | 51,353 | 55,770 | |
Net worth | Rs m | 23,357 | 36,296 | 44,925 | 51,635 | 56,052 | |
Long term debt | Rs m | 25,744 | 24,873 | 45,363 | 41,418 | 35,738 | |
Total assets | Rs m | 87,429 | 101,929 | 117,639 | 125,954 | 132,888 | |
Interest coverage | x | 4.1 | 6.8 | 7.6 | 4.9 | 4.4 | |
Debt to equity ratio | x | 1.1 | 0.7 | 1.0 | 0.8 | 0.6 | |
Sales to assets ratio | x | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | |
Return on assets | % | 7.6 | 9.0 | 11.4 | 8.6 | 9.5 | |
Return on equity | % | 20.3 | 20.5 | 24.7 | 15.6 | 16.5 | |
Return on capital | % | 16.0 | 20.0 | 19.1 | 15.1 | 17.8 | |
Exports to sales | % | 44.8 | 43.2 | 0 | 0 | 0 | |
Imports to sales | % | 7.1 | 7.4 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 29,720 | 33,044 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 4,680 | 5,672 | 0 | 0 | 0 | |
Fx inflow | Rs m | 31,299 | 36,945 | 56,152 | 36,317 | 62,998 | |
Fx outflow | Rs m | 10,856 | 61,066 | 8,084 | 9,720 | 22,859 | |
Net fx | Rs m | 20,443 | -24,122 | 48,068 | 26,598 | 40,140 |
GLENMARK PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 4,817 | 3,449 | 6,574 | 16,481 | 13,242 | |
From Investments | Rs m | -5,400 | -8,802 | -7,124 | -10,133 | -6,990 | |
From Financial Activity | Rs m | 1,992 | 6,986 | 5,432 | -4,685 | -7,387 | |
Net Cashflow | Rs m | -311 | 934 | 1,992 | 1,770 | -2,971 |
Share Holding
|
Company Information
|
CHM: Glenn Saldanha (MD) | COMP SEC: Sanjay Kumar Chowdhary | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.4 |
Read: GLENMARK PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: SUN PHARMA PROCTER & GAMBLE HEALTH J.B.CHEMICALS VENUS REMEDIES PIRAMAL ENTERPRISES
Compare GLENMARK PHARMA With: SUN PHARMA PROCTER & GAMBLE HEALTH J.B.CHEMICALS VENUS REMEDIES PIRAMAL ENTERPRISES
Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More